

Original article

Precautions are Needed for COVID-19 Patients with Coinfection of Common Respiratory Pathogens

Quan-sheng Xing^{1*#}, Guo-ju Li^{1*}, Yu-han Xing^{2*}, Ting Chen^{3*}, Wen-jie Li^{1*}, Wei Ni^{1*}, Kai Deng^{4*}, Ru-qin Gao^{5*}, Chang-zheng Chen^{2*}, Yang Gao¹, Qiang Li¹, Gui-ling Yu¹, Jian-ning Tong¹, Wei Li¹, Gui-liang Hao¹, Yue Sun¹, Ai Zhang¹, Qin Wu¹, Guang-ren Ma⁴, Zi-pu Li¹, Si-lin Pan¹

1. Qingdao Women and Children's Hospital, Qingdao University, Qingdao City, Shandong Province, China
2. Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
3. Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan City, Hubei Province, China
4. Qingdao Chest Hospital, Qingdao City, Shandong Province, China
5. Municipal Centre of Disease Control and Prevention of Qingdao, Qingdao Institute of Prevention Medicine, Qingdao City, Shandong Province, China

***Contributed equally**

#Correspondence

Quansheng Xing, MD, PhD: Qingdao Women and Children's Hospital, Qingdao University, Qingdao, Shandong Province, China, No.6 Tongfu Road, 266000, Qingdao, China. E-mail: xingqs0532@163.com

Abstract

Background: In our clinical practice, we found a large proportion of patients diagnosed with Coronavirus Disease 2019 (COVID-19) had coinfections with other seasonal respiratory pathogens in Qingdao, northeast China, which differed greatly from earlier cases reported in the epidemic center, Wuhan, central China.

Objectives: To clarify the pattern of coinfection with other common respiratory pathogens in COVID-19 patients in Qingdao and Wuhan; to explore the possible reasons underlying the between-region difference.

Methods: We conducted a double-center study and recruited 64 patients with laboratory-confirmed severe acute respiratory coronavirus 2 (SARS-CoV-2) infection from three hospitals in Qingdao and one hospital in Wuhan from January 17 to February 16, 2020. Indirect immunofluorescence (IIFA) was performed to detect the specific IgM antibody against common respiratory pathogens in collected acute phase serum.

Results: Of the 68 patients with SARS-CoV-2 infection, 30 (44.12%) were from Qingdao. The median age of Qingdao and Wuhan patients were 50 years and 31 years, respectively, and the majority of patients were female in Qingdao (60.00%) and Wuhan (55.26%). Among COVID-19 patients in Qingdao, 24 of them had IgM antibodies against at least one respiratory pathogen, and the overall positive rate was 80.00%, whereas only one (2.60%) of the patients in Wuhan had positive results for serum IgM antibody detection ($P<0.0001$). The most common respiratory pathogens detected in Qingdao COVID-19 patients were IFV-A (60.00%) and IFV-B (53.30%), followed by MP (23.30%) and LP (20.00%). Only 13.33% of healthy control group ($n=4$) had specific-IgM antibody (against IFV-B) detected in the serum, a figure significantly lower than that in COVID-19 patients in Qingdao ($P<0.0001$). None of the healthy control had combined infection. The most common respiratory pathogens detected in COVID-19 patients were IFV-A and IFV-B (23.33%); while the pattern for coinfection in patients with community-acquired pneumonia was quite different, with a coinfection rate of only 8.96%.

Interpretation: With the ongoing outbreak of COVID-19, patients within and beyond the epidemic area behaved differently. More attention should be paid for the coinfection of other respiratory pathogens in patients with COVID-19. We highly recommend adding SARS-CoV-2 to the routine testing assay in capable hospitals to prevent misdetection of the virus.

Keywords: Severe acute respiratory coronavirus 2; Coronavirus Disease 2019; Coinfection; Respiratory pathogen

Funding: This research was supported by The National Natural Science Foundation of China (NSFC) [Grant number 81770315]; and Distinguished Taishan Scholars (2019).

Conflicts of interest: The authors have no conflict of interest to declare.

Running head: Coinfection in COVID-19 patients

Introduction

At the beginning of December 2019, a cluster of “pneumonia of unknown etiology” emerged in Wuhan, Hubei Province, China. The disease has soon developed into an outbreak posing a pandemic threat. Since no causative pathogen was identified at the onset of the disease, it was once called “Wuhan pneumonia” by the health officials and the public. On December 31, 2019, a total of 27 cases were reported; meanwhile, a rapid response team led by the Chinese Center for Disease Control and Prevention (China CDC) was formed to conduct detailed epidemiologic and etiologic investigations in Wuhan [1-3]. After ruling out common respiratory pathogens such as influenza, avian influenza, respiratory syncytial virus (RSV), adenovirus (ADV), respiratory severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), etc., a novel coronavirus was confirmed as the etiological agent on January 7, 2020 and related disease was termed as Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO) [4]. Subsequent full-length genome sequencing analysis indicated that the newly discovered virus, now known as severe acute respiratory coronavirus 2 (SARS-CoV-2), belongs to a distinct beta-coronavirus genus of probable bat origin [5, 6]. Thus far, the epidemic has swept through the nation. As of February 29, 2020, the number of laboratory or clinical confirmed cases in China has increased to approximately 80,000, causing over 2,800 death [7]. The fast-growing outbreak has affected over fifty countries and regions including Hong Kong, Vietnam, South Korea and the USA [8-10], constituting a public health emergency of international concern [11].

Surprisingly, we found a large proportion of coinfection with other seasonal respiratory pathogens in COVID-19 patients admitted to hospitals in Qingdao, Shandong Province, northeast China, which differed from those of the primary infected patients from the epidemic center, Wuhan, central China [3, 12]. To determine such between-region difference and to explore the possible reasons behind it, we conducted this double-center study recruiting COVID-19 patients admitted in both Qingdao and Wuhan hospitals. We hope our study will

provide a new perspective on prevention and management of COVID-19 patients and to facilitate a better understanding of the disease.

Methods

Study areas

We chose Qingdao and Wuhan as the study centers to investigate the difference in coinfection with common respiratory pathogens among COVID-19 patients. **Figure 1** showed the geographical location of two cities. As depicted, Qingdao is situated about 850 kilometers northeast of Wuhan.

Participants

We recruited patients with laboratory-confirmed COVID-19 who admitted to the 3 designated hospitals in Qingdao (Qingdao Women and Children's Hospital, Affiliated Hospital of Qingdao University Medical College, and Qingdao Chest Hospital) and Renmin Hospital of Wuhan University from January 17 to February 16, 2020. Laboratory testing was done for all patients for the detection of SARS-CoV-2 and other respiratory pathogens. All patients were diagnosed as COVID-19 according to WHO interim guidance and were defined as non-severe [4]. Seven cases in Qingdao were not included in demographic and clinical analysis due to lack of related information. To test the reliability of pathogen detection method, we random selected 16 healthy blood donors and 14 asymptomatic individuals who came to the hospitals in Qingdao for health counselling as the group for quality control (healthy control group). In addition, 67 patients with community-acquired pneumonia (CAP) who admitted to the local hospitals in Qingdao at the same time were enrolled as a comparable group to COVID-19 patient group (CAP control group). Diagnosis of CAP was based on the latest clinical guideline [13]. The epidemiological characteristics, clinical presentations, and laboratory findings were extracted from electronic medical records. Radiographic evidence included chest X-ray or computed tomography. Laboratory assessments consisted of blood routine, blood biochemistry, liver function and C-reactive protein measurements.

This study was approved by the Ethics Commission of each participating hospital (QFFLL-KY-2020-11) and written informed consent was obtained from involved patients prior to enrollment.

Detection of SARS-CoV-2 in respiratory samples

Laboratory testing of SARS-CoV-2 was done in clinical laboratory of individual hospital within 2 hours after sample collection; samples collected in Qingdao were also double-tested

by Qingdao Center for Disease Control (Qingdao CDC). Upper respiratory tract specimens (throat swabs) were obtained from all patients upon admission using standardized techniques in negative-pressure isolation rooms. After collection, throat swab was kept in 1.5 mL virus preservation solution for subsequent extraction of total RNA using a magnetic bead-based kit (HEALTH BioMed Co., Ltd, Ningbo, China). The presence of SARS-CoV-2 was detected by real-time quantitative reverse-transcriptase-polymerase-chain reaction (RT-PCR). Both the commercial kits used in Qingdao (DAAN Gene Co., Ltd of Sun Yat-sen University, China) and Wuhan (GeneoDX Co., Ltd, Shanghai, China) were approved by the China Food and Drug Administration (CFDA). For samples tested in Qingdao, the PCR assay simultaneously amplified two target genes of SARS-CoV-2 included open reading frame 1ab (*ORF1ab*) and nucleocapsid protein (N) and the sequences were as follows: forward primer 5'-CCCTGTGGGTTTTACTTAA-3', reverse primer 5'-ACGATTGTGCATCAGCTGA-3'; and the probe 5'-FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'. Amplification was performed under the following conditions: incubation at 50 °C for 15 min and 95 °C for 15 min, followed by 45 cycles of denaturation at 95 °C for 15 sec, and extending and collecting fluorescence signal at 55 °C for 15 sec (7500 Real-Time PCR Systems, Applied Biosystems™, Thermo Fisher Scientific). A cycle threshold (Ct) value no more than 40 with evident amplification curve was considered as a positive test, and a Ct value over 40 was defined as a negative result. Procedures of viral detection done in Wuhan was described elsewhere [14].

Detection of serum IgM antibody against respiratory pathogens

Laboratories in Qingdao and Wuhan applied a similar protocol for detection of IgM-specific antibodies against respiratory pathogens in collected acute phase serum. Indirect immunofluorescence (IIFA) was performed to detect serum IgM antibody by using a commercially available kit (samples collected from Qingdao patients: EUROIMMUN Medizinische Labor diagnostika AG, CN; samples collected from Wuhan patients: Vircell, S.L., Santa Fe, Granada, Spain) according to the manufacturer's instructions [15]. IIFA can detect 9 of the common respiratory pathogens including respiratory syncytial virus (RSV), adenovirus (ADV), influenza A virus (IFV-A), influenza B virus (IFV-B), parainfluenza virus (PIV), *mycoplasma pneumonia* (MP), *chlamydia pneumoniae* (CP), *legionella pneumophila* (LP) and *Q fever pneumonia* (COX) in a single assay. Briefly, diluted serum solution (1:100 for detection of LP and 1:10 for other pathogens) was incubated on each well of the slide and stained with fluorescein-conjugated antibodies. The multi-well slide was then processed for fixing, staining, washing and drying steps, the entire well containing the stained specimen

was examined under an epifluorescence microscope. RT-PCR nucleic acid detection was also performed in respiratory specimens collected from Wuhan patients for detection of other 13 respiratory viruses including IFV-A, H1N1, H3N2, IFV-B, PIV, RSV, human metapneumovirus, SARS-CoV, rhinovirus, ADV, Bocavirus, MP and CP.

Statistical analysis

Raw data were entered by two persons (double data entry) who were not aware of the arrangement of study groups. Continuous variables (non-normal distribution) were expressed as median with interquartile range (IQR) and compared with the Mann-Whitney U test; categorical variables were presented as number (%) and compared by χ^2 test or Fisher's exact test between Wuhan and Qingdao groups. A two-sided α of less than 0.05 was considered statistically significant. Statistical analyses were done using the SAS software, version 9.4.

Results

By February 16, 2020, a total of 68 patients with laboratory-confirmed SARS-CoV-2 infection was included in the final analysis, among whom 30 were from Qingdao and 38 were from Wuhan (**Table 1**). The median age of Qingdao and Wuhan patients were 50 years (IQR: 37-59) and 31 years (IQR: 28-38), respectively. The median duration from symptom onset to hospitalization was 2.0 days (IQR: 0.0-5.0) for patients in Qingdao and 4.0 days (IQR: 2.0-5.0) for that in Wuhan. The majority of patients admitted in Qingdao and Wuhan hospitals were female, representing a proportion of 60.00% and 55.26%, respectively. The most common symptoms at onset of COVID-19 were fever (66.67% vs. 57.89%) and cough (50.00% vs. 68.42%) in both Qingdao and Wuhan patients. Over one third of the Qingdao patients had underlying diseases (36.67%), a proportion much higher than that of Wuhan patients (2.63%). In comparison with Wuhan patients, Qingdao patients were older, had a higher respiratory rate (20 breaths/min [IQR: 19-21] vs. 19 breaths/min [IQR: 18-20]) and increased diastolic blood pressure (77 mmHg [IQR: 70-84] vs. 72 mmHg [IQR: 70-77]; all P values less than 0.05). On admission, white blood cell and platelet counts of Qingdao patients were higher than those of Wuhan patients (median white blood cell count: $5.11 \times 10^9/L$ [IQR: 4.15-6.10] vs. $4.17 \times 10^9/L$ [IQR: 3.50-5.60], $P=0.0401$; median platelet count: $237 \times 10^9/L$ [IQR: 165-265] vs. $166 \times 10^9/L$ [IQR: 148-207], $P=0.0043$). The median total bilirubin level was 12.50 $\mu\text{mol/L}$ (IQR: 10.50-15.50) in Qingdao patients, which was significantly higher than that in Wuhan patients (7.14 $\mu\text{mol/L}$ [IQR: 5.70-9.70], $P=0.0016$).

All patients had respiratory specimens tested for specific IgM antibodies against IFV-A, IFV-B, RSV, ADV, PIV, MP, LP, CP and COX. Among the 30 patients admitted in Qingdao, 24 patients had IgM antibodies detected against at least one of the above-mentioned pathogens, and the overall positive rate was 80.00% (**Table 3**); whereas only one (2.60%) of the patients in Wuhan had positive results for respiratory pathogens. The most common respiratory viruses detected were IFV-A (60.00%) and IFV-B (53.33%), followed by MP (23.33%) and LP (20.00%).

Ages of the healthy control group ranged from 20 to 55 years, with a median age of 40 years (IQR: 33-50), and 14 (46.67%) were men. Only 4 people (13.33%) of this group had specific-IgM antibody detected in their serum, suggesting asymptomatic infection with single virus (IFV-B). The total infection rate in healthy control was significantly lower than that in COVID-19 patients ($P < 0.0001$, **Table 4**), and none of the normal individual in control group had combined infection.

Figure 2 showed the rate of coinfection with other respiratory pathogens detected in Qingdao COVID-19 patients as compared with CAP controls. The overall positive rate for coinfection in CAP group was 20.90%, significantly lower than the figure in COVID-19 patients (80.00%, $P = 0.0055$). Except for SARS-CoV-2, 7 (23.33%) COVID-19 patients had mixed infections of IFV-A and IFV-B, 6 (20.00%) patients of this group had 3 respiratory pathogens (IFV-A, IFV-B and MP/LP) detected, and 13.33% of them had combined infection of IFV-B only. Whereas in CAP group, patients were more often coinfecting with IFV-B and MP (8.96%), followed by a combination of IFV-A and MP (4.48%), and IFV-A and RSV (2.99%). Thus it can be seen that COVID-19 patients had distinct etiological features of coinfection from CAP patients in Qingdao.

Table 5 showed the climatic characteristics of Qingdao and Wuhan from December to January of following year, where differences could be observed between the two cities. Although the climate in Qingdao is drier and colder than Wuhan, major respiratory pathogens circulate in the two cities were quite similar.

Discussion

This is an extended descriptive study on COVID-19 patients between Wuhan and Qingdao, represented as within and beyond the epidemic center, respectively. Since the early onset of COVID-19 till the specific definition of novel coronavirus (previously known as 2019-nCoV) releasing on January 7, 2020 [4], the term “illness/pneumonia of unknown etiology” was repeatedly quoted by the health officials and the public during this one-month period. One of

the possible explanations for such failure to clearly define the disease is that no causative pathogen could be found at the early stage. We speculated that if any common respiratory pathogen, such as influenza and parainfluenza viruses, RSV, ADV, MP and CP, or the previous emerging novel coronaviruses including SARS-CoV and MERS-CoV, was isolated from body fluids and secretions of the infected patients, related treatment and management could have been implemented in the first place. As such, it was very unlikely that “pneumonia of unknown causes” would still be emphasized, although this might cause delay in the discovery of SARS-CoV-2. Therefore, we assumed that the possibility of coinfection in COVID-19 patients was very rare. Our assumption was led support by two recent studies conducted in Wuhan showing that there was no coinfection of respiratory pathogens in COVID-19 cases [3, 12].

According to our data, the vast majority of COVID-19 patients in Qingdao were not from the endemic area; they were infected indirectly without a history of traveling to Wuhan. Despite the high coinfection rate in COVID-19 patients in Qingdao, there are no signs of worsening of these patients’ clinical manifestations or prognosis of the disease. A study conducted in Zhejiang Province, China revealed that COVID-19 patients outside of Wuhan had relatively mild symptoms as compared with those initially reported in Wuhan [16]. Like patients in Qingdao, these Zhejiang patients had no direct contact with the original site of outbreak (Wuhan Huanan Seafood Market). Evidence is scarce at the present stage to explain whether it is due to the weakening of SARS-CoV-2 virulence during virus transmission. Previous studies on SARS have shown that the disease was more infectious at an earlier stage when compared to the later stage [17]. The global mortality rate of MERS was about 40% and declined sharply to less than 20% during second generation transmission [18]. Currently, our first priority is to slow transmission of SARS-CoV-2. Some of the patients are still under hospitalized treatment or under isolation, requiring a multidisciplinary approach to illustrate the underlying mechanisms in the future.

Here we also compared the geographical and climatic characteristics of Qingdao and Wuhan. Wuhan is located in the center of southern China and has a subtropical climate [19, 20]; while Qingdao is situated in the coastal area of northern China in the temperate zone, which has a relatively lower humidity than Wuhan [21]. Despite the difference in natural characteristics between the two cities, common respiratory pathogens circulate in Wuhan and Qingdao. Wuhan (including IFV-A, IFV-B, RSV, and ADV) have shown to be generally similar during the peak season of respiratory diseases in wintertime (from January to February) [22-25]. The incidence of coinfection in COVID-19 patients in Wuhan was rather

low. However, in places with relatively low temperature like northern Qingdao, it is more common to find combined SARS-CoV-2 infection with other seasonal respiratory pathogens. It is still unclear whether this phenomenon also exists in other regions, leaving a gap for future studies. There are limited data to address whether coinfection with other respiratory viruses would affect the pathogenesis and outcome of severe acute respiratory illnesses like SARS and MERS [26-30].

Fortunately, all of our patients were found to have SARS-CoV-2 infection before coinfection being detected. Otherwise these COVID-19 patients would have been treated in the way as infected with other respiratory pathogens, which might result in devastating consequences. Our findings provide some important implications for the prevention and management of COVID. First of all, it is very effective and efficient for the China CDC and local governments to launch series of aggressive measures to screen, monitor, isolate, diagnose, and treat suspected patients and their close contacts in response to the widespread transmission of the virus. Moreover, we must remain vigilant when dealing with COVID-19 cases in other locations outside of Wuhan. Even common respiratory pathogens are detected by diagnostic testing, we still need to rule out the possibility of SARS-CoV-2 infection. In light of the emergence of coinfecting COVID-19 cases, there might be a long-term coexistence of SARS-CoV-2 with humans, just as other seasonal respiratory pathogens. Last but not least, we highly recommend adding SARS-CoV-2 to the clinical testing assay as soon as possible, in a manner as how we routinely detect influenza and parainfluenza viruses, RSV, ADV, MP and CP, etc. Our hospitals adopted the above-mentioned screening and surveillance protocol right after the recognition of first coinfecting COVID-19 case. Further detailed investigations should aim to ascertain the exact reasons underlying the high coinfection rate outside of Wuhan.

It is notable that there are several limitations of this study. Two critically ill patients and one patient who died in the end were excluded due to lack of etiological data other than SARS-CoV-2. As of February 16, 2020, there were 60 cases of confirmed SARS-CoV-2 infection in Qingdao, however, we only analyzed 30 non-severe cases whose complete etiological and clinical information was available. The age of patients in Qingdao ranged from 1.5 years to 80 years; whereas patients in Wuhan were all adults as they were medical staff infected in the hospital. Such age difference between the two groups might bring in bias to this study. We performed nucleic acid testing for the confirmation of SARS-CoV-2 infection, while coinfection with other pathogens was detected by serological testing of antibodies. In spite of superior accuracy, PCR-based molecular testing requires more

complicated techniques of laboratory personnel with prolonged reporting time, which may not be suitable for emerging cases of SARS-CoV-2 [31, 32]. Thus, we applied rapid testing of etiological agents by IIF to guide clinical decision making. Since both the hospitals in Qingdao and Wuhan adopted the same protocol for the diagnosis of coinfections, we believe this will not affect the determination of final outcomes. To test the reliability of serum specific IgM detection, we recruited a control group of normal people without clinical symptoms. The low infection rate in our control population suggested that our method was reliable in early and rapid diagnosis of respiratory infections. However, we were unable to exclude the possibility that coinfection with other respiratory pathogens may make the patients more susceptible to SARS-CoV-2 infection. Specific-IgM antibody could be detected within one week after onset of infection and can last for 1-3 months in the serum [33]. Positive results for serum IgM antibody detection only indicate infection with specific pathogens during the past one to two months, but cannot tell the time sequence of coinfection with various pathogens. Whether immune regulation associated with earlier infection with common respiratory pathogens confers an element of protection against the pathological damage caused by subsequent infection of SARS-CoV-2 remains unanswered.

Till now, the epidemic is still expanding with the number of infected patients escalating rapidly, and the situation in countries and regions beyond China presents a more dismal picture. Recently, WHO upgraded the risk assessment of SARS-CoV-2 to very high; as of 28 February 2020, a total of 4,351 cases in 49 countries, and 67 deaths have been reported outside China [11]. Hence, we call for a timely action to carry out real-time research on the epidemic dynamic of SARS-CoV-2.

References

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *Journal of medical virology* 2020;**92**(4):401-02 doi: 10.1002/jmv.25678[published Online First: Epub Date].
2. Hui DS, E IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases* 2020;**91**:264-66 doi: 10.1016/j.ijid.2020.01.009[published Online First: Epub Date].

3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;**395**(10223):497-506 doi: 10.1016/S0140-6736(20)30183-5[published Online First: Epub Date].
4. WHO. WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Secondary WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 11, 2020. [https://www.who.int/internalpublicationsdetail/clinicalmanagementofsevereacuterespiratoryinfectionwhennovelcoronavirus\(ncov\)infectionissuspected](https://www.who.int/internalpublicationsdetail/clinicalmanagementofsevereacuterespiratoryinfectionwhennovelcoronavirus(ncov)infectionissuspected) (accessed Jan 20, 2020).
5. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020 doi: 10.1038/s41586-020-2012-7[published Online First: Epub Date].
6. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New England journal of medicine* 2020;**382**(8):727-33 doi: 10.1056/NEJMoa2001017[published Online First: Epub Date].
7. China NHCotPsRo. National Health Commission of the People's Republic of China. Secondary National Health Commission of the People's Republic of China. <http://www.nhc.gov.cn> (Assessed on February 18th, 2020).
8. Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. *The New England journal of medicine* 2020 doi: 10.1056/NEJMc2001272[published Online First: Epub Date].
9. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *The New England journal of medicine* 2020 doi: 10.1056/NEJMc2001468[published Online First: Epub Date].
10. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. *The New England journal of medicine* 2020 doi: 10.1056/NEJMoa2001191[published Online First: Epub Date].
11. website. Wm. WHO main website. Secondary WHO main website. <https://www.who.int> (accessed February 28th, 2020).
12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;**395**(10223):507-13 doi: 10.1016/S0140-6736(20)30211-7[published Online First: Epub Date].

13. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019;**200**(7):e45-e67 doi: 10.1164/rccm.201908-1581ST[published Online First: Epub Date]].
14. Xu WZ, Li J, He XY, et al. The diagnostic value of joint detection of serum IgM and IgG antibodies to 2019-nCoV in 2019-nCoV infection. *Chin J Lab Med* 2020;**43**:Epub ahead of print doi: 10.3760/cma.j.cn114452-20200223-00109[published Online First: Epub Date]].
15. Hong J, Li D. Epidemiological analysis on pathogens of respiratory tract infections in children in Hubei Province (in Chinese). *Occup and Health* 2015;**31**(19):2683-86
16. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020;**368**:m606 doi: 10.1136/bmj.m606[published Online First: Epub Date]].
17. Duan CH, Liu XM, Wang HY, et al. The Clinical Study of SARS Patients Combined with the Infection of *Mycoplasma Pneumoniae* (in Chinese). *Journal of Tropical Medicine* 2003;**3**(3):290-91
18. Kim KH, Tandil TE, Choi JW, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. *J Hosp Infect* 2017;**95**(2):207-13 doi: 10.1016/j.jhin.2016.10.008[published Online First: Epub Date]].
19. Hao J, Yang Z, Yang W, et al. Impact of Ambient Temperature and Relative Humidity on the Incidence of Hand-Foot-Mouth Disease in Wuhan, China. *International journal of environmental research and public health* 2020;**17**(2) doi: 10.3390/ijerph17020428[published Online First: Epub Date]].
20. Li X, Ying W, Jiangfeng L, et al. Physical and Socioeconomic Driving Forces of Land-Use and Land-Cover Changes: A Case Study of Wuhan City, China. *Discrete Dynamics in Nature and Society*;**2016**:1-11
21. Pan S, Ni W, Li W, et al. Effects of PM_{2.5} and PM₁₀ on congenital hypothyroidism in Qingdao, China, 2014-2017: a quantitative analysis. *Therapeutic advances in endocrinology and metabolism* 2019;**10**:2042018819892151 doi: 10.1177/2042018819892151[published Online First: Epub Date]].

22. Li X, Fang B, Ye GJ, et al. Epidemiological characteristics of children respiratory tract viral infection in Hubei area (2012-2017) (in Chinese). *J of Pub Health and Pre Med* 2019;**1**(30):30-33 doi: 10.1016/j.bbmt.2020.02.014[published Online First: Epub Date]].
23. Ye JH, Cao Q, Feng L, et al. Neotropical *Anopheles* (Kerteszia) mosquitoes associated with bromeliad-malaria transmission in a changing world. *Acta tropica* 2019;**30**(1):115-18 doi: 10.1016/j.actatropica.2020.105413[published Online First: Epub Date]].
24. Wu ZG, Li ZQ, Gu J, et al. Associations between self-management behavior and sociodemographic and disease-related characteristics in elderly people with type 2 diabetes - New results from the population-based KORA studies in Germany. *Primary care diabetes* 2019;**26**(2):133-37 doi: 10.1016/j.pcd.2020.01.004[published Online First: Epub Date]].
25. Feng Z, Xiaoyan S, Dan Z, et al. Etiology spectrum of virus in acute upper respiratory infection in children from 2017 to 2018 in Qingdao. *Chin J Dis Control Prev* 2019;**23**(6):694-98
26. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *Lancet* 2003;**362**(9380):263-70 doi: 10.1016/S0140-6736(03)13967-0[published Online First: Epub Date]].
27. Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. *Nature* 2003;**423**(6937):240 doi: 10.1038/423240a[published Online First: Epub Date]].
28. Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. *Arch Dis Child Fetal Neonatal Ed* 2005;**90**(6):F461-5 doi: 10.1136/adc.2005.075309[published Online First: Epub Date]].
29. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. *Virology* 2015;**12**:222 doi: 10.1186/s12985-015-0439-5[published Online First: Epub Date]].
30. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. *The New England journal of medicine* 2003;**348**(20):1995-2005 doi: 10.1056/NEJMoa030634[published Online First: Epub Date]].
31. Landry ML. Developments in immunologic assays for respiratory viruses. *Clinics in laboratory medicine* 2009;**29**(4):635-47 doi: 10.1016/j.cll.2009.07.003[published Online First: Epub Date]].

32. Tan SZ, Lu YP, Xiano B, et al. Investigation and analysis of SARS patients with Mycoplasma pnesmoniae and Chlamydia pneumoniae complicating infection. *J Diagn Concepts Pract* 2004;**3**(5):326-29
33. Song QW, Zhu RN, Deng J, et al. [Evaluation of serum specific IgM detection in diagnosis of respiratory viral infections in children]. *Zhonghua Er Ke Za Zhi* 2012;**50**(6):440-4

Figure legends

Figure 1. Geographical location of Qingdao and Wuhan, China

Figure 2. Rate of coinfection with common respiratory pathogens in COVID-19 and CAP patients in Qingdao

Table 1. Characteristics of patients infected with SARS-CoV-2

	Qingdao (n=30)	Wuhan (n=38)	P-value
Age, y	50 (37-59)	31 (28-38)	0.0009
Male	12 (40.00)	17 (44.74)	0.6949
In hospital day	2 (0-5)	4 (2-5)	0.2350
Fever	20 (66.67)	22 (57.89)	0.4599
Cough	15 (50.00)	26 (68.42)	0.1232
Dyspnea	0 (0.00)	3 (7.89)	0.2493
Myalgia	5 (16.67)	11 (28.95)	0.2359
Headache	4 (13.33)	3 (7.89)	0.6909
Pharyngalgia	4 (13.33)	6 (15.79)	1.0000
Fatigue	8 (26.67)	15 (39.47)	0.2677
Anorexia	4 (13.33)	10 (26.32)	0.1886
Diarrhea	5 (16.67)	2 (5.26)	0.2272
Expectoration	8 (26.67)	9 (23.68)	0.7779
Dizziness	1 (3.33)	2 (5.26)	1.0000
Chest congestion	6 (20.00)	2 (5.26)	0.1256
Heart rate, bpm	79 (73-91)	78 (76-81)	0.3817
Respiratory rate, min	20 (19-21)	19 (18-20)	0.0033
SBP, mmHg	120 (114-133)	120 (117-125)	0.5596
DBP, mmHg	77 (70-84)	72 (70-77)	0.0413
Temperature, °C	36.9 (36.4-37.0)	36.6 (36.5-36.8)	0.0900
Combined diseases	11 (36.67)	1 (2.63)	0.0003
Clustering of the symptoms, ≥ 4	8 (26.67)	13 (34.21)	0.5038

The data are expressed as n (%) or median (IQR).

Table 2. Laboratory findings of patients infected with SARS-CoV-2

	Qingdao (n=30)	Wuhan (n=38)	P-value
Blood routine			
White blood cell count, $\times 10^9/L$	5.11 (4.15-6.10)	4.17 (3.50-5.60)	0.0401
Neutrophils $\times 10^9/L$	3.17 (2.62-3.59)	2.49 (1.89-3.57)	0.0788
Lymphocyte $\times 10^9/L$	1.26 (1.12-1.78)	1.19 (1.00-1.64)	0.3102
Platelet $\times 10^9/L$	237 (169-265)	166 (148-207)	0.0043
Hemoglobin, g/L	130 (123-149)	139 (128-148)	0.2239
Blood biochemistry			
Albumin, g/L	43.20 (38.80-44.40)	42.05 (40.50-44.30)	0.8012
Alanine aminotransferase,U/L	19.30 (12.00-26.00)	19.00 (13.00-31.00)	0.6213
Aspartate aminotransferase,U/L	22.00 (19.00-31.00)	21.00 (18.00-29.00)	0.4217
Total bilirubin, $\mu\text{mol/L}$	12.50 (10.50-15.50)	7.14 (5.70-9.70)	0.0016
Serum creatinine, $\mu\text{mol/L}$	61.00 (43.00-73.00)	60.00 (46.00-72.00)	0.8134
Glucose, mmol/L	5.20 (4.71-8.40)	4.91 (4.51-5.55)	0.0823
Infection-related biomarkers			
C-reactive protein, mg/L, (normal range: 0.0-10.0)			
Increased	14 (46.67)	10 (27.03)	0.0812

The data are expressed as n (%) or median (IQR).

**Table 3. Coinfection of common respiratory pathogens in COVID-19 patients
in Qingdao and Wuhan**

Pathogens detected	Qingdao (n=30)	Wuhan (n=38)	<i>P</i> -value
	No. (%)	No. (%)	
IFV-A	18 (60.00)	0 (0.00)	<0.0001
IFV-B	16 (53.33)	0 (0.00)	<0.0001
MP	7 (23.33)	1 (2.63)	0.0179
LP	6 (20.00)	0 (0.00)	0.0054
RSV	0 (0.00)	1 (2.63)	1.0000
ADV	0 (0.00)	0 (0.00)	NA
PIV	0 (0.00)	0 (0.00)	NA
CP	0 (0.00)	0 (0.00)	NA
COX	0 (0.00)	0 (0.00)	NA
Total	24 (80.00)	1 (2.63)	<0.0001

Abbreviations: influenza A virus (IFV-A), influenza B virus (IFV-B), mycoplasma pneumonia (MP), legionella pneumophila (LP), respiratory syncytial virus (RSV), adenovirus (ADV), parainfluenza virus (PIV), chlamydia pneumoniae (CP) and Q fever pneumonia(COX).


Table 4. Common respiratory pathogens detected in COVID-19 patients and healthy controls

Pathogens detected	COVID-19 patients (n=30)	Healthy controls (n=30)	<i>P</i> -value
	No. (%)	No. (%)	
IFV-A	18 (60.00)	0 (0.00)	<0.0001
IFV-B	16 (53.33)	4 (13.33)	0.0018
MP	7 (23.33)	0 (0.00)	0.0105
LP	6 (20.00)	0 (0.00)	0.0237
RSV	0 (0.00)	0 (0.00)	NA
ADV	0 (0.00)	0 (0.00)	NA
PIV	0 (0.00)	0 (0.00)	NA
CP	0 (0.00)	0 (0.00)	NA
COX	0 (0.00)	0 (0.00)	NA
Total	24 (80.00)	4 (13.33)	<0.0001

Table 5. Natural characteristics of Qingdao and Wuhan

	Qingdao	Wuhan
Average temperature (°C)	-0.2-2.5	4.0-6.2
Mean humidity (%)	63	73
Epidemic respiratory viruses	IFV-A, IFV-B, RSV, ADV	IFV-A, IFV-B, RSV, and ADV
Rate of co-infection (%)	16.3	13.6

Average temperature during December and January of following year (Average temperature), Mean humidity during December and January of following year (Mean humidity), influenza virus A (IFV-A), influenza virus B (IFV-B), respiratory syncytial virus (RSV), adenovirus (ADV).



■ CAP patients ■ COVID-19 patients

